London Healthcare Week: Manchester, UK based F2G, which booked a $100M financing in September, is focused on developing therapies for fungal infections
CEO Francesco Maria Lavino describes the unmet need in this area and the science behind how F2G combats it. Plus, learnings from an FDA CRL the current development and regulatory plan.